Latest News

Inflation data, Black Friday sales: What to know this week

0

Motley Fool

1 Cancer Stock on Buyout Watch in 2022

The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.

Suze Orman says these are America’s common money mistakes — do any of them sound familiar?

Previous article

Market is ‘one more bad inflation report’ away from a correction, Wharton’s Jeremy Siegel warns

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in Latest News